Taisho Pharmaceutical Co., Ltd.

Youichi Shimazaki

Takeshi Kuwada

Naoki Miyakoshi

Daisuke Wakasugi

Nobutaka Hattori

Tomoko Ishizaka

Shin-ichi Shirokawa

Mitsukane Yoshinaga

Shin-Ichi Shirokawa

Hiroshi Ohta

Tsuyoshi Shibata

Masato Hayashi

Shuji Yamamoto

Kazunari Sakagami

Akito Yasuhara

Yoshihisa Shirasaki

Kumi Abe

Yuko Araki

Xiang-Min Sun

The present invention provides agents for treating or preventing diseases such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, alopecia, and so forth. Specifically, the invention provides azole derivatives represented by general formula (I), or pharmaceutically acceptable salts thereof that have an antagonistic action against the arginine-vasopressin (AVP) V1b receptor: 

Azole derivative

The present invention provides a 1,2,4-triazolone derivative represented by Formula (1A) having an antagonistic activity on the arginine-vasopressin 1b receptor or a pharmaceutically acceptable salt thereof and provides a pharmaceutical composition comprising the compound or the salt as an active ingredient, in particular, a therapeutic or preventive agent exhibiting favorable pharmacokinetics in a disease such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, or alopecia. 

1, 2, 4-triazolone derivative and use thereof as an antagonist on the arginine-vasopressin 1B receptor

The present invention aims to provide novel compounds of formula [I] or pharmaceutically acceptable salts thereof that are based on a glycine uptake inhibiting action and which are useful in the prevention or treatment of such diseases as schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsory disorder, social anxiety disorder, posttraumatic stress disorder, specific phobia, acute stress disorder, etc.), depression, drug addiction, spasm, tremor, and sleep disorder: 

Glycine transporter inhibiting substances

Growing community of inventors

Toshima-ku, Japan

Youichi Shimazaki